Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

R. A. Hajjeh, L. Privor-Dumm, K. Edmond, R. O'Loughlin, S. Shetty, U. K. Griffiths, A. P. Bear, A. L. Cohen, A. Chandran, A. Schuchat, E. K. Mulholland, M. Santosham

Research output: Contribution to journalArticlepeer-review

Abstract

The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

Original languageEnglish (US)
Pages (from-to)7123-7129
Number of pages7
JournalVaccine
Volume28
Issue number43
DOIs
StatePublished - Oct 8 2010

Keywords

  • Developing countries
  • Haemophilus influenzae type b (Hib)
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience'. Together they form a unique fingerprint.

Cite this